NEW YORK — C2i Genomics said on Thursday that it has signed an agreement with Singapore-based genomic services provider NovogeneAIT Genomics to launch its C2-Intelligence Platform for minimal residual disease detection in Southeast Asia.
The C2-Intelligence Platform uses artificial intelligence pattern recognition and whole-genome analysis to detect minimal residual disease in blood samples from cancer patients. According to C2i, the platform includes whole-genome tumor profiling for increased diagnostic yield and tumor-informed blood-based MRD testing for cancer burden monitoring and personalized treatment management.
Under the terms of the deal, NovogeneAIT will act as a reference lab for the platform, deploying it in its sequencing labs in Southeast Asia. The firm has also been given a nonexclusive license to distribute and market C2i's pharmaceutical and diagnostic services in the region, which include cancer patient assessment for clinical trial enrollment.
Financial and other terms were not disclosed.
Earlier this year, C2i — a New York City-based venture between the New York Genome Center and Weill Cornell Medicine researchers — raised $100 million in private financing. NovogeneAIT is a joint venture between Chinese sequencing firm Novogene and AIT Biotech, a molecular diagnostics and genomic products developer.